Login to Your Account

Orexigen's Weight Loss Drug Shows Promise In Phase IIb

By Jennifer Boggs

Wednesday, July 25, 2007

No Abstract


Staff Writer

Orexigen Therapeutics Inc. reported positive top-line data from a Phase IIb study of Empatic, the company's second program aimed at the sizeable - and still growing - obesity market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription